DON’T MISS OUR WEBINAR: Scaling Specialty Infusion Delivery Beyond the Hospital. Register now.

Specialty drugs and infusions

Choose the leading partner for outpatient specialty drug and infusion delivery.

Current Health provides the infrastructure to allow biopharma and providers in moving the delivery of high-cost drugs and therapies into outpatient, home, and community settings.  
 
Leverage proven, evidence-based delivery models to accelerate adoption, improve safety, and expand patient access. 

Improve the economics for high-cost therapies.

Commercial success for high-cost therapies depends on sustainable delivery models.

Outpatient, community, and home-based care expand access and improve economics, but only when supported by the right infrastructure. 

Advanced therapies can’t scale on clinical protocols alone. They require real-world systems that balance safety, efficiency, and economics for all stakeholders. Our infrastructure enables therapies to move safely beyond the hospital—supporting adoption, payer alignment, and patient access while relieving pressure on inpatient capacity. 

That means real-time visibility into safety, clear escalation pathways, efficient staffing, and operations built to scale. 

A proven model for safe, scalable post-infusion care.

We’ve partnered with leading cancer centers and pharmaceutical companies to move advanced therapies—including CAR-T and bispecifics—safely into outpatient and home settings.

 

With therapy-specific protocols, neurotoxicity monitoring, and 24/7 clinical oversight, our model expands access without compromising safety or outcomes. 

Anchored in validated clinical research.

For years, our clinical research team has been partnering closely with our customers to conduct research on service evaluation and showcase clinical, operational and financial success. 

We know what works, and those learnings are baked into our care episodes.

These are some of the research questions we’ve helped answer: 

Is outpatient blinatumomab treatment feasible?

Our solution can be safely relied up on to deliver a virtual immunotherapy program and reduce hospital LOS.

Read the research. 

Successful outpatient care depends on multidisciplinary teams, rapid response protocols for managing toxicities like CRS and ICANS, and efficient patient transitions to higher-level care when needed.

Read the research.

A 15-day period is sufficient for capturing nearly all serious adverse events related to FDA-approved CAR-T products, supporting a shorter, efficient monitoring approach.

Read the research.

Accelerate adoption with payer-ready delivery models.

The success of high-cost therapies depends on real-world delivery beyond the hospital. Outpatient and community models lower total cost of care, strengthen payer negotiations, and drive broader provider uptake.

Current Health provides the infrastructure that ensures therapies like CAR-T, bispecifics, and emerging specialty drugs can be delivered safely, scalably, and credibly across diverse care settings. 

Improve trials and regulatory strategy

Incorporate outpatient/community models into late-stage R&D to accelerate recruitment, while generating robust real-world evidence.

Differentiate at launch

Build payer-ready, outpatient delivery into commercial strategy from day one.

Expand provider adoption

Enable delivery beyond early academic hubs into community networks.

Strengthen the payer story

Lower site-of-care costs improve coverage and reimbursement positioning.

Expand oncology services while keeping patients closer to home.

Advanced therapies demand high-acuity oversight, but they don’t need to stay confined to the hospital. Our model is built around the unique safety profiles of complex therapies, proven to scale therapies like CAR-T and bispecifics without compromise.

Providers can strengthen patient relationships, expand oncology services, and capture new revenue streams—all while preserving safety and clinical oversight under their own brand. 

Purpose-built for high-risk therapies

Designed around the unique safety and monitoring needs of CAR-T, bispecifics, and emerging advanced therapies.

Keeps patients connected to your team

Care remains under your clinicians and brand, strengthening loyalty and referral patterns.

Reduces inpatient strain

Proven to save bed days and optimize hospital resources, with early adopters transitioning 75%+ of CAR-T to outpatient care while maintaining safety.

Aligned to your business

Reimbursement-ready, with flexible models that ensure growth works in your favor.

Your clinical and operational infrastructure for better experiences.

How we support specialty drugs and infusions:

Therapy-specific clinical pathways

Each with predefined patient journeys, alarm parameters, and escalation protocols, ready to deploy from day one.

Continuous monitoring

Our proprietary FDA-cleared continuous wearable and connected devices feed real-time data into a centralized clinical dashboard for timely interventions.

Flexible logistics management

Integrated end-to-end device deployment and reprocessing in fully outsourced or hybrid models.

Seamless EHR integrations

Put clinical insights where care teams need them—right in your EHR. Turbocharger packages for Epic support fast implementation.

24/7 clinical oversight

Our RNs and MAs provide continuous oversight, escalating to your care team as needed to maintain safety and staffing efficiency.

Early detection of CRS

Address CRS sooner with our comprehensive solution, which can detect signs of CRS more than 3 hours earlier than standard of care.

Support for ICANS assessments

Workflows to support detection of early signs of immune effector cell-associated neurotoxicity.

In-home labs

On-demand lab draws and diagnostic testing performed through partners at the patient’s home to ensure timely clinical decision-making without requiring hospital visits.

Sneak peek

Coming soon: integrated ICANS assessments

In the coming weeks, our complex drug and infusion episodes will include daily, integrated ICANS assessments by our Clinical Command Center.

How Sarah Cannon expanded access to CAR-T and reduced inpatient strain.

Discover how Sarah Cannon reimagined CAR-T delivery—improving patient experience and easing hospital capacity constraints with a safe, scalable at-home model.

75%

Of CAR-T patients now cared for in outpatient setting

75%

Reduction in LOS for patients requiring inpatient care

1,200

Bed days saved in first 100 patients

Ready to scale specialty therapies beyond the hospital?

Let's make it happen.

Get started

Want to take something with you?

Download our white paper: Care at Home for High-Risk Oncology Patients.

Get our insights and lessons learned for bringing oncology care home.